Ultima-CJC1295 DAC at a Glance
CJC-1295 DAC is a synthetic growth hormone releasing hormone analogue peptide incorporating drug affinity complex (DAC) technology to extend its biological half-life. This modified GHRH peptide represents an advancement over standard CJC-1295 formulations through its enhanced duration of action in preclinical models. The DAC modification enables sustained growth hormone secretagogue activity, making it valuable for researchers investigating prolonged GH-axis modulation. Scientists examining growth hormone dynamics often study this compound alongside other research peptides available through specialist suppliers like Stroid UK Shop to evaluate comparative mechanisms.
Laboratory Applications
Research applications for CJC-1295 DAC encompass growth hormone pathway investigations, pituitary function studies, and metabolic research protocols. The extended half-life characteristics allow researchers to examine sustained growth hormone release patterns over prolonged observation periods. Studies typically investigate its interaction with GHRH receptors and downstream signalling cascades. Comparative analyses often evaluate this compound against standard CJC-1295 peptide formulations to assess duration differences. Research protocols may incorporate this peptide in studies examining metabolic modulation, similar to investigations conducted with SARMs for tissue-selective effects. The compound’s stability profile makes it suitable for extended research protocols where frequent dosing would confound experimental results.
Technical Specifications
| Parameter | Value |
|---|---|
| Molecular Weight | Verify with supplier |
| CAS Number | Verify with supplier |
| Purity | Research grade |
| Form | Lyophilised powder |
| Storage | -20°C, protect from light |
| Solubility | Water soluble when reconstituted |
This 2mg formulation from Ultima Pharmaceuticals provides researchers with sufficient material for multiple experimental protocols. The lyophilised format ensures stability during storage and transport. When reconstituted with appropriate bacteriostatic water, solutions should be stored at 2-8°C and used within recommended timeframes. Quality control documentation should accompany each vial to verify peptide integrity. Research involving this compound often includes comparative studies with other peptides to establish baseline activity profiles.
Compliance Statement
CJC-1295 DAC 2mg is supplied strictly for in-vitro research purposes and laboratory investigations only. This product is not intended for human consumption, clinical application, or therapeutic use. Researchers must ensure compliance with institutional guidelines and applicable regulations when handling this research compound. All experimental protocols should incorporate appropriate safety measures and waste disposal procedures consistent with laboratory best practices.
